Introduction
Temporal lobe epilepsy (TLE) is known to be the most common form of focal epilepsy in adults, and it is considered to be a polygenic and complex disorder, in which various susceptibility genes and environmental factors act in a multifactorial fashion and result in the specific clinical problem that clinicians attempt to unravel and treat in any given patient. 1, 2 To date, familial TLE with an autosomal dominant inheritance and incomplete penetrance has been recognized, but only a few chromosomal localizations and genes have been involved. 1, 2 In the last years, several putative susceptibility genes have been associated with TLE but concordance between genotype and phenotype is relatively weak. 3 Currently, there is a consensus that inflammatory process has a fundamental role in the pathogenesis of TLE. Although, the exact molecular pathogenic mechanism of TLE still remains unclear, there is solid evidence that inflammatory mediators may be activated in a variety of focal epilepsies including TLE, and that a persistent upregulation of inflammatory gene expression may contribute to its pathogenesis. 4, 5 Toll-like receptor 4 (TLR4) is one of the key immune system effectors and dysregulation of TLR4 signalling owing to single nucleotide polymorphisms (SNPs) may alter the ligand binding and balance between pro-and antiinflammatory cytokines, thereby modulating the risk of chronic inflammation and contribute to an individual's susceptibility to various complex diseases. 6 Coding variants in Toll-like receptor 4 (TLR4) gene have been reported to be associated with inflammatory diseases. 6 According to the above data, and in view of the pivotal role of innate immunity in the pathogenesis of TLE, we hypothesized that TLR4 may represent a reasonable functional candidate gene for TLE. Using a case-control approach, this study considers the inflammation hypothesis by exploring risks associated with a functional single nucleotide polymorphism, dbSNP rs4986790: A>G, at position 896 (referred to as Asp299Gly) from the transcriptional start site of TLR4 gene, which is known to attenuate receptor signalling. 7 We also investigated whether this variant could influence the main clinical variables of TLE.
Materials and methods
Data and evaluation procedures on our TLE patients have been reported in greater detail elsewhere. 8, 9 The study group included Genomic DNA was extracted from venous blood using standard procedures. Patients and controls were genotyped for the rs4986790: A>G variant in the TLR4 gene using TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA). Assay conditions were in accordance with manufacturers' protocols. Fluorescence outputs were quantified in real time by using a 7900HT Fast Real Time PCR System, and the data were analyzed using SDS software, version 2.2.2 (Applied Biosystems). In the first step, we assessed statistical differences between patients and controls in relation to the rs4986790 variant. In the second step, we only studied the patient group and evaluated the relationship between the rs4986790 variant and clinical variables that included age, gender, age at onset of epilepsy, duration of epilepsy and response to antiepileptic drugs (AEDs). Genotype and allele frequencies, and Hardy-Weinberg equilibrium tests of the TLR4 SNP were performed separately among cases and controls using the chi-square test (x 2 test). C 2 analysis was used to test significance of differences in allele and genotype frequencies in controls versus affected subjects. Odds ratios and 95% confidence intervals (CIs) were calculated according to a multivariate logistic regression model adjusted for age and sex. Qualitative variables are expressed as percentage with odds ratio (95% CI), and quantitative variables are expressed as mean AE SD. In all tests, a p value below 0.05 was considered significant. The previously mentioned statistical analyses were performed with the Statistical Package for Social Science software (SPSS, version 12.0, Chicago, IL) for Windows. The statistical power required to achieve statistically significant associations were carried out with version 3.1 of G*Power programme, 11 URL: http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/. The estimated effect size was calculation based on the present study size (370 for control group and 345 for case group) using a two independent sample test with a power of 80% at two-sided type I error rate 0.05. The analysis of minimal statistical power was performed post hoc with the G*Power programme.
Results
Analysis of genotype or allelic frequencies between patients and controls showed no statistically significant difference (p = 0.512 and p = 0.245, respectively) ( Table 1 ). In the second step of the study, we observed that the SNP rs4986790 did not influence age at seizure onset or duration of epilepsy. There was also no overrepresentation of this SNP in patients with MRI evidence of Hs. Also, we investigated the relationship between this variant and response to AEDs, stratifying the patients into two groups: 90 patients with drug-resistant and 244 patients with drug-responsive focal epilepsy. For the latter analysis, we excluded 11 patients for whom their last follow-up was not available. We did not observe differences between groups regarding the responsiveness to AEDs. These results are presented in Table 2 .
Discussion
The TLR4 gene plays an important role in modulating the risk of chronic inflammation and, therefore, it may contribute to the pathophysiology of TLE, in which in which inflammatory processes play an important role. In this study, we tested the hypothesis that the functional SNP A>G in TLR4, 896 nucleotides downstream of the transcription start site, which alters the ligand-binding receptor site, is associated with disease susceptibility. Although TLR4 gene may be a plausible candidate gene for TLE, our results have illustrated that the rs4986790 does not seem to play a major role in TLE pathogenesis nor does it influence major clinical variables of TLE.
TLE has a wide heterogeneous clinical presentation from severe forms in some patients to very mild in others, suggesting that this syndrome might origin from a combination of environmental and genetic factors. 13 Genes known to be involved in biologic mechanisms that can result in disease development are ideal candidates to target for genetic etiological involvement. Association studies represent a powerful approach for identifying genetic susceptibility factors underlying common aetiological disorders such as TLE, so the genetic background is also important in modulating disease phenotype. Genetic factors have been commonly implicated in the aetiology of TLE, however the precise mechanism and amount of genetic contribution are not fully determined. 9, 12 We are aware, however, of the limits and subtle biases of any association study, 13 and the association for an obvious candidate gene requires examination in other populations and further genetic and molecular studies are required to fully elucidate the role of TLR4 in the susceptibility to TLE. In this way, it is also possible that larger populations may allow depicting a role of the TLR4 variant allele in TLE. So, we await further studies in independent population samples to confirm our results. Nonetheless, it should be noted that in our study the controls were adequately matched to the cases for ethnicity, and all patients as well as controls are Caucasian and were born in Italy. It is therefore reasonable to speculate that our patients represent an appropriate study group to depict any genetic contribution to TLE.
In conclusion, these findings provide the first epidemiologic evidence evaluating whether a genetic variant in the TLR4 gene may increase the risk of developing TLE. Although pro-inflammatory TLR4 SNPs might have a major influence on the production of inflammatory mediators, 14 the SNP rs4986790 has no contribution to TLE in the case-control association study, and further studies are needed to investigate the effect of genetic networks and their interactions in TLR4 signalling pathway and TLE susceptibility.
